Zhejiang Maitong Biopharmaceutical Co., Ltd. develops first-in-class small molecule inhibitors targeting metabolic enzymes associated with tumorigenesis, specifically for treating glioma and acute myeloid leukemia. Their lead candidate, the IDH1 inhibitor MT-001, has received clinical trial approval and aims to improve treatment outcomes for patients with these aggressive cancers.
Funding
Funding not disclosed
Founders
Product
Problem
Glioma and acute myeloid leukemia are aggressive cancers with limited effective treatment options, resulting in poor patient outcomes. Current therapies often fail to completely eradicate the tumor cells or are associated with significant toxicities, highlighting the need for more targeted and effective treatments.
Solution
Maitong Biopharmaceutical is developing first-in-class small molecule inhibitors that target metabolic enzymes critical for tumorigenesis, offering a novel approach to cancer treatment. Their lead candidate, MT-001, is an IDH1 inhibitor designed to selectively block the activity of the IDH1 enzyme, which is frequently mutated in glioma and acute myeloid leukemia. By inhibiting IDH1, MT-001 aims to disrupt cancer cell metabolism, induce cell death, and ultimately improve treatment outcomes for patients with these cancers. MT-001 has received clinical trial approval and is currently undergoing Phase I/IIa clinical trials to assess its safety and efficacy. The company is also developing inhibitors for IDH2, Me3, IRG1, MTA-PRMT5, and WRN.
Target Audience
The primary target audience includes patients diagnosed with glioma and acute myeloid leukemia, as well as oncologists and hematologists seeking more effective and targeted treatment options for these cancers.
Features
- MT-001: A first-in-class small molecule inhibitor targeting the IDH1 enzyme.
- Selective inhibition of IDH1 to disrupt cancer cell metabolism.
- Ongoing Phase I/IIa clinical trials to evaluate safety and efficacy in glioma and acute myeloid leukemia patients.
- Pipeline of additional small molecule inhibitors targeting IDH2, Me3, IRG1, MTA-PRMT5, and WRN.
- Development platform encompassing target compound design, drug screening, in vivo efficacy testing, and CMC.